By Mukundan Sivaraj · AIM Media House
Drugmaker Novo Nordisk said April 14 it is partnering with OpenAI to apply artificial intelligence across drug discovery and business operations.
The company said the collaboration will use advanced AI to analyze complex datasets, identify drug candidates, and reduce the time required to move treatments from research to patient use, according to its official announcement.
Novo said the partnership will integrate OpenAI’s AI capabilities across its global operations, including research, manufacturing, supply chain, distribution, and commercial functions. Chief Executive Officer Mike Doustdar said the company is applying AI to improve how it discovers and develops treatments.
He said the technology allows researchers to analyze data at a larger scale, identify patterns, and test hypotheses more quickly. Doustdar said there are therapies yet to be discovered for patients with obesity and diabetes, and the company is using AI to accelerate the search for new treatment options.
OpenAI Chief Executive Officer Sam Altman said AI can support scientific discovery and improve health outcomes. He said the collaboration will help accelerate research and improve how global operations are run.
Novo said OpenAI will support workforce development by helping employees build AI skills and improve productivity across teams. The company said it is expanding AI use across departments through training and internal adoption.
The company said pilot programs will begin across research and development, manufacturing, and commercial operations. It said full integration of AI systems is planned by the end of 2026.
Novo said the partnership includes data protection, governance, and human oversight to ensure compliant use of AI systems across its operations.
Continue on AIM Media House